Pre-market Hot Trades in US Stocks
Vicor is down 7.06% in pre-market trading. Based on recent key news:
<ol>
<li>
On May 13, several executives at Vicor, including Michael McNamara and Claudio Tuozzolo, conducted large-scale stock sales, leading to increased market concerns about internal confidence in the company, putting pressure on the stock price. Source: EDGAR
</li>
<li>
On May 14, Alex Gusinov sold 1,502 shares of Vicor, further exacerbating market concerns about internal turmoil within the company, causing the stock price to continue to decline. Source: MT Newswires
</li>
<li>
On May 12, Doyle Alvaro sold shares at a price of $286.9102 per share, totaling $1,159,404. The market became uneasy about the frequent stock sales by company executives, leading to a drop in the stock price. Source: SEC Filing. Vicor has performed well year-to-date, with increased market volatility.
</li>
</ol>
Applied Digital is down 5.03% in pre-market trading. Based on recent news:
<ol>
<li>
On May 13, Applied Digital announced that it may purchase more shares or sell and allocate shares based on the performance and options of ChronoScale. This news raised uncertainty about the company's future strategy, leading to a decline in the stock price.
</li>
<li>
On May 14, data showed that Applied Digital's short interest ratio was 28.02%. High short interest typically indicates strong bearish sentiment in the market towards the stock, further intensifying downward pressure on the stock price. Recent technology stocks have shown overall weak performance, and market sentiment is cautious.
</li>
</ol>
Top Gainers in Pre-market Trading of US Stocks
HCW Biologics is up 194.78% in pre-market trading. Based on recent news:
<ol>
<li>
On May 14, HCW Biologics announced that its candidate drug HCW11-040 is being studied for the prevention of bronchopulmonary dysplasia (BPD) in IND-enabled research, with completion of the study and submission of the IND application expected in the second half of 2027. This discovery significantly boosted market confidence in the company's future development, driving the stock price sharply higher.
</li>
<li>
On May 14, HCW Biologics released its Q1 2026 financial report, reporting earnings per share of $0.37, exceeding market expectations. The financial report showed significant progress in the field of innovative integrated immunotherapy, further enhancing investor confidence.
</li>
<li>
On May 14, analysts rated HCW Biologics as &#34;Buy,&#34; setting a 12-month target price of $2.00, approximately 472.4% higher than the closing price of $0.35 on May 13. This optimistic analyst rating and target price expectation provided strong support for the stock price. The biotechnology and medical research industry has shown strong performance recently, with investor sentiment high
Dreamland pre-market rose by 97.50%. Based on recent news,
</li>
<li>
On May 12, Dreamland announced that its subsidiary Trendic International signed a memorandum of understanding with LinkFung Innovation to develop and deploy a comprehensive AI smart image library platform. This collaboration is expected to leverage the complementary strengths of both companies, driving market expansion and profitability, which in turn boosts the stock price.
</li>
<li>
On May 13, Dreamland's stock price surged by 126.92%, closing at $2.36, with a trading volume of approximately $219 million. Such an extreme single-day increase is typically accompanied by specific event-driven factors or concentrated speculative inflows, indicating the market's high optimism about the company's future development.
</li>
<li>
On May 14, technical indicators showed that Dreamland's stock price was severely overbought, with an RSI of 97.75, and the stock price was 839.7% above the 20-day moving average and 1,478.3% above the 50-day moving average. This extreme technical performance further fueled market speculation. There have been no significant sector-wide positive developments in the film and entertainment industry recently, highlighting the market's speculative nature.
</li>
</ol>
Auddia pre-market rose by 69.67%. Based on recent news,
<ol>
<li>
On May 15, Auddia submitted an S-4 form to merge with Thramann Holdings to establish a unified AI platform. Following this announcement, the market expressed optimism about the prospects of the merged entity, leading to a significant rise in the stock price.
</li>
<li>
On May 12, Auddia's directors and executives were considered participants in the proxy solicitation, further boosting market confidence in the merger, resulting in a rise in the stock price.
</li>
<li>
On May 12, Auddia published an announcement on its official website detailing information related to the merger transaction, enhancing investor confidence and consequently driving up the stock price. The market is optimistic about the prospects of the AI platform, which has propelled the stock price upward
</li>
</ol>

VICR

APLD

Vicor pre-market down 7.06%; Applied Digital pre-market down 5.03%; HCW Biologics pre-market up 194.78%; Dreamland pre-market up 97.50%; Auddia pre-market up 69.67%

Price Alert

Vicor

Pre-market hot trades in US stocks: Vicor pre-market down 7.06%; Applied Digital pre-market down 5.03%